Bod Australia appoints leading executive as CFO

|

Published 12-APR-2021 12:05 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Cannabis centric healthcare company Bod Australia Limited (ASX: BDA) has announced the appointment of accomplished senior accounting and financial management executive Mr Alan Dworkin as Chief Financial Officer, effective 3rd May 2021.

Mr Dworkin is a highly successful and results-driven, with over 20 years’ experience in finance and operations management. He has a demonstrated ability to streamline business operations, drive growth and increase efficiency and bottom-line profit.

“We are very pleased to welcome Alan to BDA’s management team. We are confident that his extensive experience in the pharmaceutical, R&D and nutraceutical sectors will be imperative in BDA’s next phase of growth, Bod CEO Jo Patterson said.

“Alan’s defined skillset in accounting and financial management will allow BDA to continue to grow its revenue profile, reduce operating expenses and streamline operational processes, which will further assist Bod in its development.

During his career, Mr Dworkin has held a number of roles in small and large businesses, including ASX-listed companies in the sales, pharmaceutical research and mining resources sectors. He has considerable expertise in developing and implementing financial controls, as well as operational improvement and managing internal and external processes.

Alan was CFO and Company Secretary of FIT Bioceuticals Limited and instrumental in its sale to Blackmores Limited

Most recently CFO, COO and Company Secretary of Medlab Clinics Limited (ASX: MDC) playing a large part in the company’s ASX float and growth trajectory.

BDA will leverage Mr Dworkin’s established skillset to drive financial growth, as well as his background in medicinal cannabis, nutraceutical product development and supply chain management to further optimise its operations.

“I am excited to be joining BDA’s management team during such a pivotal growth phase, incoming CFO Alan Dworkin added.

"BDA is currently delivering a number of innovative products to international markets, which are underpinned by stringent R&D initiatives. The Company has a number of near-term opportunities at its disposal and I look forward to deploying my skillset to unlock further value for shareholders.”

About BOD Australia

Bod Australia is a medicinal cannabis, CBD and hemp healthcare products company, with a global focus and a mission to innovate and transform the way we live and enjoy life.

The company is focused on delivering premium, proven and trusted products for both consumer markets and medical markets, and leading the way in research and development through collaborations with research partners on clinical trial programs.

Additionally, BDA is committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

For more about BDA read: More US Sales Expected. BDA Fully Funded for Manufacturing Requirements



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X